News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
852,761 Results
Type
Article (86869)
Company Profile (704)
Press Release (765186)
Multimedia
Podcasts (145)
Webinars (19)
Section
Business (232814)
Career Advice (4132)
Deals (39763)
Drug Delivery (129)
Drug Development (91106)
Employer Resources (198)
FDA (18186)
Job Trends (17363)
News (396838)
Policy (39823)
Tag
Academia (3002)
Academic (2)
Accelerated approval (11)
Adcomms (32)
Allergies (106)
Alliances (56975)
ALS (119)
Alzheimer's disease (1565)
Antibody-drug conjugate (ADC) (187)
Approvals (18136)
Artificial intelligence (396)
Autoimmune disease (37)
Automation (18)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (135)
Biotechnology (481)
Bladder cancer (100)
Brain cancer (40)
Breast cancer (390)
Cancer (3077)
Cardiovascular disease (247)
Career advice (3540)
Career pathing (34)
CAR-T (209)
CDC (40)
Cell therapy (572)
Cervical cancer (24)
Clinical research (74292)
Collaboration (1107)
Company closure (3)
Compensation (711)
Complete response letters (33)
COVID-19 (2904)
CRISPR (67)
C-suite (350)
Cystic fibrosis (120)
Data (3072)
Decentralized trials (2)
Denatured (51)
Depression (76)
Diabetes (380)
Diagnostics (6979)
Digital health (26)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (179)
Drug pricing (152)
Drug shortages (36)
Duchenne muscular dystrophy (132)
Earnings (97500)
Editorial (48)
Employer branding (25)
Employer resources (169)
Events (131451)
Executive appointments (909)
FDA (19914)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1014)
Gene editing (147)
Generative AI (39)
Gene therapy (436)
GLP-1 (934)
Government (5259)
Grass and pollen (6)
Guidances (181)
Healthcare (20917)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (184)
Immuno-oncology (10)
Indications (40)
Infectious disease (3100)
Inflammatory bowel disease (163)
Inflation Reduction Act (13)
Influenza (71)
Intellectual property (124)
Interviews (813)
IPO (17906)
IRA (55)
Job creations (5193)
Job search strategy (2863)
Kidney cancer (15)
Labor market (56)
Layoffs (590)
Leadership (26)
Legal (10137)
Liver cancer (85)
Lung cancer (432)
Lymphoma (215)
Machine learning (11)
Management (65)
Manufacturing (440)
MASH (99)
Medical device (14724)
Medtech (14729)
Mergers & acquisitions (22576)
Metabolic disorders (964)
Multiple sclerosis (104)
NASH (23)
Neurodegenerative disease (142)
Neuropsychiatric disorders (41)
Neuroscience (2318)
NextGen: Class of 2025 (7687)
Non-profit (5090)
Now hiring (48)
Obesity (493)
Opinion (290)
Ovarian cancer (103)
Pain (119)
Pancreatic cancer (125)
Parkinson's disease (201)
Partnered (25)
Patents (316)
Patient recruitment (167)
Peanut (55)
People (65709)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (22935)
Phase II (32259)
Phase III (24286)
Pipeline (1686)
Policy (241)
Postmarket research (3552)
Preclinical (10354)
Press Release (72)
Prostate cancer (149)
Psychedelics (45)
Radiopharmaceuticals (279)
Rare diseases (522)
Real estate (7402)
Recruiting (76)
Regulatory (27166)
Reports (61)
Research institute (2665)
Resumes & cover letters (650)
Rett syndrome (10)
RNA editing (10)
RSV (58)
Schizophrenia (98)
Series A (172)
Series B (118)
Service/supplier (30)
Sickle cell disease (67)
Special edition (22)
Spinal muscular atrophy (168)
Sponsored (37)
Startups (4304)
State (2)
Stomach cancer (17)
Supply chain (83)
Tariffs (65)
The Weekly (92)
Vaccines (917)
Venture capital (57)
Weight loss (330)
Women's health (51)
Worklife (20)
Date
Today (44)
Last 7 days (443)
Last 30 days (2003)
Last 365 days (34032)
2025 (18300)
2024 (38139)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1273)
Alabama (70)
Alaska (7)
Arizona (280)
Arkansas (14)
Asia (50529)
Australia (8878)
California (7766)
Canada (2408)
China (725)
Colorado (340)
Connecticut (346)
Delaware (205)
Europe (115920)
Florida (1154)
Georgia (263)
Hawaii (2)
Idaho (66)
Illinois (741)
India (32)
Indiana (385)
Iowa (18)
Japan (237)
Kansas (115)
Kentucky (33)
Louisiana (18)
Maine (73)
Maryland (1101)
Massachusetts (5948)
Michigan (275)
Minnesota (483)
Mississippi (3)
Missouri (100)
Montana (32)
Nebraska (26)
Nevada (82)
New Hampshire (73)
New Jersey (2178)
New Mexico (31)
New York (2183)
North Carolina (1244)
North Dakota (10)
Northern California (3344)
Ohio (251)
Oklahoma (17)
Oregon (48)
Pennsylvania (1660)
Puerto Rico (18)
Rhode Island (39)
South America (1654)
South Carolina (36)
South Dakota (1)
Southern California (2871)
Tennessee (128)
Texas (1185)
United States (29342)
Utah (230)
Virginia (211)
Washington D.C. (80)
Washington State (686)
West Virginia (4)
Wisconsin (85)
There are 852,761 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
The Gap Between Administration’s Pro-Innovation Words and Policy
Despite the FDA commissioner’s promises of partnership and collaboration, personnel changes and continued federal cuts create uncertainty for an industry already struggling with nearly half a decade of investment scarcity.
July 14, 2025
·
6 min read
·
Lori Ellis
Cardiovascular disease
AstraZeneca’s Baxdrostat Pushes Blood Pressure Lower in Phase III Trial
The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its cardiovascular and kidney disease pipelines.
July 14, 2025
·
1 min read
·
Dan Samorodnitsky
Layoff Tracker
Massachusetts-Based Karyopharm, Azurity Cut Workforces
Follow along as
BioSpace
tracks job cuts and restructuring initiatives throughout 2025.
July 14, 2025
·
158 min read
·
BioSpace Editorial Staff
Neuroscience
Takeda Establishes Lead in Narcolepsy Race With Back-to-Back Phase III Wins
Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical significance,” according to Jefferies analysts.
July 14, 2025
·
2 min read
·
Tristan Manalac
Depression
After Three Strikes, Relmada Abandons Depression Drug Esmethadone
The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage trials.
July 14, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
The FDA cited manufacturing issues but did not flag problems with Ultragenyx’s data package for UX111, with the biotech noting that the regulator found its neurodevelopmental findings for the gene therapy to be “robust.”
July 14, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Mulls Speedier Reviews to Companies Willing To Lower Drug Costs
Through its recently unveiled Priority Voucher program, the FDA seeks to accelerate the review process for companies that promise to keep prices down.
July 14, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Waters and BD’s Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
July 14, 2025
·
23 min read
Press Releases
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
July 14, 2025
·
8 min read
Press Releases
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
July 14, 2025
·
4 min read
1 of 85,277
Next
